Comparison of Tirzepatide and Semaglutide in weight loss using a balance scale illustration.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, and dual GLP-1 RA/gastric inhibitory polypeptide (GIP) agonists, like tirzepatide, have garnered significant attention for their promising results in weight reduction. These agonists operate by mimicking incretin hormones, which help regulate glucose levels and appetite. A recent study, published in the JAMA Internal Medicine, highlighted the comparative efficacy of these medications. Conducted by a research team from Truveta and Providence Heart Institute, this study demonstrated that tirzepatide offers superior efficacy compared to semaglutide in adults struggling with overweight or obesity. The findings underscore the potential of tirzepatide as a more effective option for weight management in this population.

 

Key Findings

Tirzepatide users experienced significantly greater weight loss compared to those on semaglutide. At 12 months, 81.8% of tirzepatide users achieved at least 5% weight loss, compared to 66.5% of semaglutide users. For higher weight loss thresholds, 62.1% versus 37.1% achieved at least 10%, and 42.3% versus 18.1% achieved at least 15% weight loss, respectively.

Weight reduction is higher in tirzepatide compared to semaglutide

The mean weight change for tirzepatide users was -15.3% at 12 months, while semaglutide users saw a -8.3% change. Adjusted differences at 3, 6, and 12 months were -2.4%, -4.3%, and -6.9%, favoring tirzepatide.

Sensitivity analyses confirmed significant weight loss differences between semaglutide and tirzepatide

Sensitivity analyses showed that modified ITT (intention-to-treat) analyses resulted in fewer patients achieving weight loss milestones, with smaller reductions and slightly reduced effect estimates. Despite this, tirzepatide led to significantly greater weight loss than semaglutide. After one year, 71.1% of patients on tirzepatide achieved 5% or greater weight loss compared to 56.4% on semaglutide. Mean weight changes were smaller but still favored tirzepatide at 3, 6, and 12 months. Adjusted analyses confirmed significant weight loss differences, and sensitivity analyses using inverse probability of treatment weighting supported these findings.

Clinical Implications

The findings highlight the superior efficacy of tirzepatide over semaglutide in achieving substantial weight loss among adults with overweight or obesity. This suggests that tirzepatide may be a more effective option for significant weight management in this population. However, further studies are warranted to explore other clinical outcomes and long-term effects.

Differences Between Tirzepatide and Semaglutide: Molecular and Mechanism of Action

The following table highlights the key similarities and differences between semaglutide and tirzepatide.

FeatureSemaglutideTirzepatide
Molecular FeaturesSynthetic analog of human GLP-1 composed of 31 amino acids; GLP-1 receptor agonist.Dual GLP-1/GIP receptor agonist; synthetic linear peptide composed of 39 amino acids.
Chemical ModificationsModified backbone and fatty acid side chain to increase stability and prolong half-life; binds to albumin to reduce renal clearance.Modifications enhance binding to albumin; fatty acid chains extend half-life; activates both GLP-1 and GIP receptors.
GLP-1 Receptor ActivationEnhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, reduces appetite.Similar effects as semaglutide: enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, reduces appetite.
GIP Receptor ActivationNot applicable.Stimulates insulin secretion; enhances insulinotropic effect of GLP-1; anabolic effect on adipose tissue, enhancing metabolic benefits.
Insulin SecretionEnhances glucose-dependent insulin secretion from pancreatic beta cells.More robust insulin response due to combined GLP-1 and GIP receptor activity.
Glucagon SecretionSuppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output.Suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output.
HbA1c ReductionEffective in lowering HbA1c and promoting weight loss, slightly less effective compared to tirzepatide at equivalent doses.More effective than semaglutide in reducing HbA1c levels and promoting weight loss.
Adverse EffectsSimilar rates of gastrointestinal side effects such as nausea and vomiting; overall tolerability profile is comparable to tirzepatide.Similar rates of gastrointestinal side effects such as nausea and vomiting; overall tolerability profile is comparable to semaglutide.
Additional EffectsSlows gastric emptying, prolongs feeling of fullness, reduces appetite, influences brain centers regulating appetite, promotes satiety.Delays gastric emptying, reduces food intake, promotes weight loss by increasing satiety, increases adiponectin levels involved in glucose and lipid metabolism.

Conclusion

In the realm of anti-obesity treatments, tirzepatide has emerged as a potent alternative to semaglutide, offering greater weight loss benefits. As obesity continues to be a global health challenge, such advancements provide hope for better therapeutic strategies. Clinicians should consider these findings when prescribing weight loss medications, balancing efficacy with patient-specific factors and potential adverse events.

References

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories